William Resh, MD
Cardiovascular Disease · Las Vegas, NVNPI 1083637235
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,200 of the $39,257 with a category attached, or 84.6%. Biotronik Inc. accounts for 84.8% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $24,659 and has fallen 95.5% since, to $1,100 in 2025. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $173.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$33K
- Acutus Medical, Inc.$1K
- Novartis$698
- Abbott$538
- Johnson & Johnson$461
- E.r. Squibb & Sons, L.L.C.$461
- plus $3K from 24 others
What the payments were for
- Consulting fees$33,20085%
- Travel & lodging$3141%
- Food & beverage$5,65614%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 26 | $33,292 |
| Acutus Medical, Inc. | 11 | $1,160 |
| Novartis | 37 | $698 |
| Abbott | 5 | $538 |
| Johnson & Johnson | 28 | $461 |
| E.r. Squibb & Sons, L.L.C. | 26 | $461 |
| Merck | 12 | $224 |
| Amgen | 7 | $223 |
| Boston Scientific | 7 | $222 |
| Kestra Medical Technology Services, Inc. | 5 | $203 |
| Infobionic, Inc | 1 | $199 |
| Impulse Dynamics (USA) Inc. | 2 | $181 |
| W. L. Gore & Associates, Inc. | 1 | $170 |
| Pfizer | 8 | $127 |
| Abiomed | 14 | $126 |
| Scpharmaceuticals Inc. | 3 | $117 |
| Baxter Healthcare | 1 | $112 |
| Sanofi-aventis U.S. LLC | 6 | $101 |
| Axonics, Inc. | 1 | $91 |
| Alnylam Pharmaceuticals Inc. | 4 | $89 |
| Lexicon Pharmaceuticals, Inc. | 3 | $81 |
| Boehringer Ingelheim | 4 | $71 |
| Bridgebio Pharma, Inc. | 2 | $69 |
| Astellas Pharma US Inc | 3 | $54 |
| Cleerly, Inc. | 1 | $50 |
| Bayer | 3 | $49 |
| Novo Nordisk | 2 | $34 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Cvrx, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edora$5,600
- Plexa$4,000
- Rivacor$4,000
- Sentus$4,000
- Acticor$4,000
- Rivacor 7 DR-T$1,600
- AVEIR$242
- MoMe Device$199
- GORE TAG Thoracic Branch Endoprosthesis$170
- CARDIOMEMS$160
- OPTIMIZER SMART SYSTEM$138
- Repatha$119
- FLOSEAL$112
- GALLANT$105
How this compares
$39,257 in reported general payments places this provider in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 487 | $592,271 |
| VyndamaxTafamidis | 25 | $591,068 |
| XareltoRivaroxaban | 297 | $398,349 |
| EntrestoSacubitril/Valsartan | 156 | $236,264 |
| MultaqDronedarone Hcl | 83 | $125,131 |
| FarxigaDapagliflozin Propanediol | 86 | $110,669 |
| JardianceEmpagliflozin | 65 | $93,566 |
| Repatha SureclickEvolocumab | 80 | $81,186 |
| VascepaIcosapent Ethyl | 32 | $29,964 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $14,020 |
| Repatha PushtronexEvolocumab | 13 | $8,855 |
| Rosuvastatin Calcium | 389 | $8,148 |
| Metoprolol Succinate | 543 | $7,414 |
| Nebivolol Hcl | 87 | $6,911 |
| Ezetimibe | 191 | $6,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $127 | $1,183,340512 claims |
| Johnson & JohnsonXarelto | $461 | $398,349297 claims |
| NovartisEntresto | $698 | $236,264156 claims |
| Sanofi-aventis U.S. LLCMultaq | $101 | $125,13183 claims |
| Boehringer IngelheimJardiance | $71 | $93,56665 claims |
| Esperion Therapeutics, Inc.Nexlizet | $17 | $14,02012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
- Dalia HawwassLas Vegas$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.